<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442974</url>
  </required_header>
  <id_info>
    <org_study_id>ABX271-PA09EU</org_study_id>
    <nct_id>NCT01442974</nct_id>
  </id_info>
  <brief_title>Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer</brief_title>
  <official_title>Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Hospital de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Hospital de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Targeting tumor stroma is emerging as a strategic approach for pancreatic cancer treatment.&#xD;
      Actually, one of the most interesting characteristics of pancreatic cancer is the dense&#xD;
      fibrotic stroma surrounding tumor cells. Moreover, pancreatic cancer stroma seems to express&#xD;
      a specific protein profile different from tumor cells. For example, secreted protein rich in&#xD;
      cysteine (SPARC) is overexpressed in pancreatic tumor stroma fibroblast and downregulated in&#xD;
      tumor cells. This characteristic is associated with poor clinical outcome.&#xD;
&#xD;
      Nab-paclitaxel, an albumin bound nano formulation of paclitaxel that targets SPARC, decreases&#xD;
      tumor stroma density. Such effect improves drug delivery, and enhances both, nab-paclitaxel&#xD;
      and gemcitabine, antitumor activity in nude mouse models.&#xD;
&#xD;
      Based on this pre-clinical data the investigators designed a clinical trial of nab-paclitaxel&#xD;
      in combination with gemcitabine as neo-adjuvant treatment for pancreatic cancer patients.&#xD;
      Fifteen, SPARC positive patients, will be enrolled in the study and treated with abraxane in&#xD;
      combination with gemcitabine.&#xD;
&#xD;
      This is a pilot study which primary end point is evaluating the effect of Abraxane in&#xD;
      combination with gemcitabine on tumor stroma, and the secondary end-point is correlating&#xD;
      these changing with treatment activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase: Pilot study to assess nab-paclitaxel in combination with gemcitabine effects on&#xD;
      pancreatic cancer stroma and tumor metabolism.&#xD;
&#xD;
      Study Objective(s):&#xD;
&#xD;
      A) Primary end-points:&#xD;
&#xD;
        1. Evaluate the effect of nab-paclitaxel in combination with gemcitabine on tumor stroma&#xD;
           density.&#xD;
&#xD;
        2. Evaluate the effect of nab-paclitaxel on tumor vessels formation.&#xD;
&#xD;
        3. Evaluate the effect of nab-paclitaxel on tumor metabolism.&#xD;
&#xD;
      B) Secondary end-point:&#xD;
&#xD;
      1. Evaluate combination activity in relation with changes in tumor stroma and tumor metabolic&#xD;
      activity.&#xD;
&#xD;
      The following studies will be performed prior and after treatment administration:&#xD;
&#xD;
        -  18FDG-PET/CT scan;&#xD;
&#xD;
        -  Ultrasound Elastography;&#xD;
&#xD;
        -  IHC:&#xD;
&#xD;
             1. SPARC;&#xD;
&#xD;
             2. Microvessel Density (CD-31, VEGF-A);&#xD;
&#xD;
             3. Stroma density (SMA and Collagen I).&#xD;
&#xD;
      Study population and Number of subject: A total of 15 pancreatic cancer patients with&#xD;
      resectable/resectable borderline disease are expected to be enrolled.&#xD;
&#xD;
      Study design and schedule: This is a pilot study to evaluate the effect of nab-paclitaxel on&#xD;
      tumor stroma in pancreatic cancer patients. The study will be conducted in two parts:&#xD;
&#xD;
      Part A: Patients diagnosed with resectable/resectable pancreatic cancer will be screened for&#xD;
      SPARC expression. Fifteen, SPARC positive patients, will be enrolled in the study and treated&#xD;
      with nab-paclitaxel in combination with gemcitabine. Patients will be treated as follow:&#xD;
&#xD;
        -  nab-paclitaxel will be administered at 125 mg/m2 as intravenous (i.v.) infusion over 30&#xD;
           minutes;&#xD;
&#xD;
        -  followed by gemcitabine 1000 mg/m2 i.v. infusion over 30 minutes;&#xD;
&#xD;
      Treatment will be delivered weekly, for 3 weeks (on day 1, 8, and 15 over 28 days cycle)&#xD;
      followed by a week of rest, for two cycles of treatment.&#xD;
&#xD;
      Part B: At the end of treatment tumors will be surgically resected according to standard&#xD;
      surgical procedure for the treatment of pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of nab-paclitaxel on pancreatic cancer stroma, new vessel formation and tumor cell metabolism.</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Primary End-point:&#xD;
Evaluate the effect of nab-paclitaxel in combination with gemcitabine on tumor stroma density.&#xD;
Evaluate the effect of nab-paclitaxel on tumor vessels formation.&#xD;
Evaluate the effect of nab-paclitaxel on tumor metabolism by PET-CT scan measuring pre-treatment versus post-treatment glucose uptake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activity of nab-paclitaxel in combination with gemcitabine against PDA in relation with changes in tumor stroma and tumor metabolic activity.</measure>
    <time_frame>up to 18 months</time_frame>
    <description>To assess secondary end-point the following studies will be performed&#xD;
18FDG-PET/CT scan;&#xD;
Ultrasound Elastography;&#xD;
IHC:&#xD;
SPARC;&#xD;
Microvessel Density (CD-31, VEGF-A);&#xD;
Stroma density (SMA and Collagen I).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus nab-paclitaxel</intervention_name>
    <description>Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles</description>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>2'-deoxy-2',2''-difluorocytidine-5'-O-monophosphate</other_name>
    <other_name>Abraxane</other_name>
    <other_name>ABI007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are 18 years or older;&#xD;
&#xD;
          -  Patients with resectable/resectable borderline pancreatic cancer;&#xD;
&#xD;
          -  Adequate hematopoietic, hepatic and renal function:&#xD;
&#xD;
               -  Neutrophil count &gt; o = 1.5 x 109/L;&#xD;
&#xD;
               -  Platelet count &gt; o = 100 x 109/L;&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x ULN;&#xD;
&#xD;
               -  AST and/or ALT ≤ 2.5 x ULN;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
          -  Investigators must ensure that patients enrolled in the study will be available for&#xD;
             all study procedures, including tumor biopsy, surgical treatment, and follow up.&#xD;
&#xD;
          -  Investigators must ensure that patients have the ability to understand the&#xD;
             requirements of the study and provide signed informed consent.&#xD;
&#xD;
          -  Signed Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or uncontrolled infections or serious illnesses or medical conditions that&#xD;
             could interfere with patient eligibility for treatment;&#xD;
&#xD;
          -  History of any psychiatric condition that might impair patient's ability to understand&#xD;
             or to comply with the requirements of the study or to provide informed consent;&#xD;
&#xD;
          -  Concurrent anticancer therapy;&#xD;
&#xD;
          -  Pregnant or breast-feeding women (documented methods of birth control are required in&#xD;
             those with reproductive potential);&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study drugs;&#xD;
&#xD;
          -  History of life threatening reaction to gemcitabine or abraxane;&#xD;
&#xD;
          -  Previous exposure to other agents or treatment procedure as radiotherapy for the&#xD;
             treatment of pancreatic cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Integral Oncologico Clara Campal (CIOCC), Centro National Investigacion Oncologica (CNIO)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Hospital de Madrid</investigator_affiliation>
    <investigator_full_name>Sofia Perea, Director Clinical Trials Unit.</investigator_full_name>
    <investigator_title>Director Clinical Research Unit</investigator_title>
  </responsible_party>
  <keyword>nab-paclitaxel</keyword>
  <keyword>neoadjuvant treatment</keyword>
  <keyword>SPARC</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

